Metformin

Evidence Limitation: The provided studies do not contain specific safety data for metformin. The clinical trials listed include metformin as part of combination therapies or comparisons, but detailed safety outcomes are not available in the abstracts provided. Therefore, this safety summary is limited by the lack of direct evidence from the provided sources.

Known Side Effects

Based on the available evidence, specific side effect profiles for metformin cannot be detailed from the provided studies. The research focuses primarily on other medications (GLP-1 receptor agonists) and general drug safety monitoring systems rather than metformin-specific adverse events.

Contraindications

The provided evidence does not contain information about metformin contraindications. One study mentions familial partial lipodystrophy syndrome with concurrent genetic variants, but does not specifically address metformin contraindications in this context.

Drug Interactions

No specific drug interaction data for metformin is available in the provided evidence. The studies focus on other therapeutic areas and do not address metformin's interaction profile.

Special Populations

Pregnancy: Limited evidence is available from the ongoing POEM Study (NCT02947503), which is investigating pregnancy outcomes with metformin use, but results are not yet available. Another diabetes in pregnancy study (NCT05932251) has been suspended, providing no additional safety data.

Evidence Gap: The current evidence base provided does not include comprehensive safety data for metformin across different patient populations.

Clinical Trial Safety Monitoring

Several ongoing clinical trials are evaluating metformin's long-term safety and efficacy (NCT06141980, NCT06627322), but results are not yet available from the provided evidence.

Disclaimer: This safety summary is based solely on limited evidence provided and does not constitute personalized medical advice. Patients should consult healthcare providers for comprehensive safety information and individual risk assessment before starting or continuing metformin therapy.

Note: The evidence provided is insufficient to provide a comprehensive safety profile for metformin. Healthcare providers should consult current prescribing information and established clinical guidelines for complete safety data.